UV light is an established carcinogen, yet evidence suggests that UV-seeking behavior has addictive features. Following UV exposure, epidermal keratinocytes synthesize proopiomelanocortin (POMC) that is processed to melanocyte-stimulating hormone, inducing tanning. We show that, in rodents, another POMC-derived peptide, b-endorphin, is coordinately synthesized in skin, elevating plasma levels after lowdose UV. Increases in pain-related thresholds are observed and reversed by pharmacologic opioid antagonism. Opioid blockade also elicits withdrawal signs after chronic UV exposure. This effect was sufficient to guide operant behavioral choices to avoidance of opioid withdrawal (conditioned place aversion). These UV-induced nociceptive and behavioral effects were absent in b-endorphin knockout mice and in mice lacking p53-mediated POMC induction in epidermal keratinocytes. Although primordial UV addiction, mediated by the hedonic action of b-endorphin and anhedonic effects of withdrawal, may theoretically have enhanced evolutionary vitamin D biosynthesis, it now may contribute to the relentless rise in skin cancer incidence in humans.
INTRODUCTION
Despite widespread awareness that UV exposure is a major risk factor for all common cutaneous malignancies, skin cancer incidence relentlessly increases by $3% per year (de Gruijl, 1999; Gandini et al., 2011; Robinson et al., 1997) . UV-seeking behavior is a recognized risk factor, but it is incompletely understood whether the popularity of sunbathing represents a biological addiction or an aesthetic preference for tanned skin. Studies have reported that many UV seekers meet CAGE and DSM-IV criteria for a substance-related disorder with respect to UV (Harrington et al., 2011; Kourosh et al., 2010; Lazovich et al., 2010; Mosher and Danoff-Burg, 2010; Warthan et al., 2005) and that UV seekers were capable of distinguishing between true UV and mock treatment in blind tanning bed experiments (Feldman et al., 2004) , and two studies of small cohorts of frequent tanners revealed that acute administration of the opioid antagonist naltrexone can induce withdrawal-like symptoms (Kaur et al., 2005 (Kaur et al., , 2006b . Although a mechanism for such addiction has been lacking, these studies are consistent with the possibility of endogenous opioid-mediated addictive behavioral effects.
In the cutaneous response to UV exposure, epidermal keratinocytes respond to DNA damage via p53-mediated transcriptional induction of the proopiomelanocortin (POMC) gene (Cui et al., 2007) . POMC is posttranslationally cleaved into biologically active peptides, one of which is a-melanocyte-stimulating hormone (a-MSH), which mediates the tanning process by stimulating adjacent melanocytes to produce the brown/black pigment eumelanin (D'Orazio et al., 2006) . The endogenous opioid b-endorphin is also posttranslationally generated in skin by cleavage of the POMC propeptide in response to UV radiation (Cui et al., 2007; Skobowiat et al., 2011; Slominski and Wortsman, 2000) . b-endorphin is the most abundant endogenous opioid, with basal plasma levels of 1-12 pM (Bender et al., 2007; Fassoulaki et al., 2007; Leppä luoto et al., 2008) , and intravenous administration of b-endorphin has been shown to cause analgesia (Tseng et al., 1976) . It binds with high affinity to the m-opioid receptor (Schoffelmeer et al., 1991) , although some evidence suggests that it may also act through other mechanisms that are, at present, incompletely characterized (Nguyen et al., 2012) . Exogenous opioids with similar mechanisms are analgesic and have reinforcing properties that make them addictive when administered systemically. Chronic opioid exposure results in tolerance (increasing dose requirement to achieve comparable efficacy) and physical dependence (opioid antagonism produces withdrawal). b-endorphin plays a role in analgesia (Ibrahim et al., 2005; Kastin et al., 1979) , as well as in the reinforcement and reward that underlie addiction (Gianoulakis, 2009; Olive et al., 2001; Racz et al., 2008; Roth-Deri et al., 2003; Trigo et al., 2009 ). Here, we asked whether UV exposure may stimulate changes in systemic b-endorphin levels that result in opioid-related behaviors, including alterations in nociceptive thresholds, tolerance to exogenous opioids, and dependence, as measured by withdrawal signs and conditioned place preference.
RESULTS

Systemic b-Endorphin Elevations following Chronic UV Exposure
We developed a UV-exposure mouse model in which dorsally shaved mice received a dose of 50 mJ/cm 2 of UVB 5 days per week for 6 weeks, an empirically derived suberythemic dose that is approximately equal to 20-30 min of ambient midday sun exposure in Florida during the summer for a fair-skinned person of average tanning ability (Fitzpatrick skin phototypes 2-3) (D'Orazio et al., 2006; Technology Planning and Management Corporation, 2000; US-EPA, 1994) . After 1 week, significant elevations in circulating plasma b-endorphin were observed ( Figure 1A ). Circulating b-endorphin levels remained elevated for the duration of the 6-week exposure regimen and returned within 7 days to near-baseline levels after cessation of UV exposure. No significant changes in plasma b-endorphin were observed in mock-UV-treated mice ( Figure 1A ). Analgesic thresholds can be increased by peripheral administration of exogenous opioids or b-endorphin (Kastin et al., 1979) . We quantified mechanical and thermal nociceptive thresholds over 6 weeks of daily UV exposure. Mechanical nociception was measured by the von Frey test (Kwan et al., 2006) , which exposes fibers of increasing tensile strength to the plantar paw surface to elicit a paw-withdrawal response. Thermal nociception was tested using the hot-plate (52 C) test (Mogil et al., 1999) , in which time to response (paw licking, paw flutter, or jumping) was measured. UV-irradiated mice exhibited significant increases both in mechanical ( Figure 1B ) and thermal ( Figure 1C ) nociceptive thresholds. These elevated analgesic thresholds paralleled the UV-induced elevations in plasma b-endorphin ( Figure 1A ). Mock-treated control mice displayed no significant elevations in pain thresholds (Figures 1B and 1C) . Treatment with naloxone, an opioid antagonist, 15 min prior to analgesic testing suppressed the UV-induced increases in mechanical and thermal nociceptive thresholds ( Figures 1B and 1C ) despite maintained elevations in plasma b-endorphin ( Figure 1A ). These data demonstrate opioid receptor-mediated analgesia as a consequence of UV that parallels the elevation of circulating blood b-endorphin.
Quantifiable Opioid-Mediated Behaviors Occur with Chronic UV Exposure Exogenous opioids produce a dose-dependent, m-opioid receptor-mediated contraction of the sacrococcygeus dorsalis muscle at the tail base in rodents, resulting in rigidity and elevation of the tail, a phenomenon called ''Straub tail'' (Bilbey et al., 1960) . Straub tail was evident in UV-irradiated mice by the second week of daily UV exposure, persisted for the 6 week exposure regimen, and diminished over 2 weeks after cessation of UV (Figure 2A) . Treatment with the opioid antagonist naloxone (day 23 of the UV-exposure regimen) reversed the Straub tail phenotype ( Figures 2B and 2C ).
Opioid Tolerance and Physical Dependence after Chronic UV Exposure We next asked whether chronic UV exposure may be accompanied by detectable opioid dependence, in which opioid cessation or antagonism produces withdrawal symptoms, and tolerance in which increasing doses are required to achieve comparable analgesia (Drdla et al., 2009) . Following chronic daily UV exposure, administration of naloxone elicited many of the classic murine signs of opioid withdrawal (wet dog shake, paw tremor, teeth chatter, and rearing) (Olson et al., 2006) ( Figure 3A) .
Because the magnitude of the measured withdrawal symptoms, while significant, was smaller than that commonly observed with exogenously administered opioids (Broseta et al., Mice were treated twice a week with either naloxone or saline as indicated. Data are presented as the mean ± SEM, and a two-way ANOVA analysis with Bonferroni multiple comparisons test gives p < 0.05 for both UV-treated groups compared to both mock-treated groups (during UV treatment, days 14-42) and no significant effect of naloxone treatment within either group.
(B and C) Von Frey thresholds (B) and hot-plate thresholds (C) in chronically UV-irradiated and mock-irradiated C57Bl6 mice (mean ± SEM). Half of each group was pretreated with naloxone (10 mg/kg) 15 min prior to nociceptive testing, while the remainder received saline (n = 10 per group). Analgesic thresholds were further monitored for 2 additional weeks after cessation of UV/mock treatment. Two-way ANOVA with Bonferroni multiple comparisons test reveals p < 0.0001 for the UV/saline-treated group compared to all other groups during UV treatment, days 9-39).
2002), we wished to determine whether these withdrawal signs would be sufficient to elicit alterations in proactive/operant behavioral choices. We utilized a conditioned place preference/aversion assay (CPP; Skoubis et al., 2001; Weitemier and Murphy, 2009 ) to test whether a specific environment, paired with naloxone administration during conditioning, would be avoided in favor of a different environment paired with a neutral stimulus (saline) during conditioning in chronically UV-irradiated animals. Due to the kinetics of the UV response, we chose to use naloxone as it allowed an acute effect of limited duration. Naloxone induces conditioned place aversion in exogenous opioid-dependent mice (Glass et al., 2008; Kenny et al., 2006) . Following conditioning, mice are permitted to move freely between the two environments, and changes in place preference are measured in the absence of additional naloxone or saline administration. Our conditioning environments were black and white boxes with dim and bright lighting, respectively, and to minimize apparatus bias, we assigned the black box as the naloxone (withdrawal stimulus)-paired box and the white box as the saline (neutral stimulus)-paired box, as rodents prefer dark environments to light environments in the absence of conditioning (Roma and Riley, 2005) .
We observed that chronically UV-irradiated mice conditioned with naloxone in the black box avoided the black box in postconditioning preference testing. Naloxone conditioning had no effect on mock-treated (non-UV-irradiated) control mice, and saline conditioning in the black box had no effect on UV-irradiated or mock-treated mice ( Figure 3B ). Here, naloxone was sufficient to induce conditioned place aversion in UV-irradiated mice, suggesting that chronic UV exposure imparts an opioid-like physical dependence of sufficient magnitude to guide proactive behavior choices.
To test for the other principal feature of chronic opioid exposure, tolerance, after chronic UV treatment, we asked whether there is cross-tolerance between chronic UV exposure and morphine, altering the dose required to produce analgesia (Mao et al., 2000) . After chronic UV exposure, mice required significantly higher doses of morphine than mock-treated controls to achieve comparable thermal analgesia in the hot-plate test, as reflected by a rightward shift in the dose-response curve and an increase in half-maximal effective concentration from 57 mg/kg in the mock-treated group to 270 mg/kg in the UV-exposed group ( Figure 3C ). The analgesic effect of UV exposure that we detected could be a result of systemic b-endorphin acting both through the peripheral nervous system and CNS, but the withdrawal effects and conditioned place aversion point to a CNS effect. It has been reported that radiolabeled b-endorphin peptides cross the blood-brain barrier (Banks and Kastin, 1990) . To test whether it is plausible that skin-derived b-endorphin may cause central effects, we decided to assess whether peripherally administered b-endorphin injected intravenously into the tail vein could cause conditioned place preference. To attempt to match an acute intravenously administered drug dose with a chronic elevation, we chose a b À endorphin concentration reported to cause a similar analgesic response to that we observed in our UV-exposure experiments, (Tseng et al., 1976) . b-endorphin or saline was injected into the tail vein of mice that were then conditioned to the white side of the CPP apparatus. The mice that had been conditioned with saline spent less time in the white box on the final day than on the initial day ( Figure 3D) ; this was expected, as mice naturally prefer a dark environment. However, the mice that had received b-endorphin in the white box spent more time in the white box after conditioning ( Figure 3D ), indicating a conditioned place preference for the environment where they experienced b-endorphin. This shows that peripherally administered b-endorphin can cause conditioned place preference, presumably through the CNS.
These findings show that chronic UV exposure stimulates and sustains sufficient endogenous opioid release and opioid receptor activity to develop both opioid tolerance and physical dependence.
b-Endorphin Knockout Abolishes UV-Induced Behavioral Changes
To specifically examine the functional requirement for b-endorphin in these UV-associated behavioral changes, we employed b-endorphin knockout mice (lacking the C terminus of the POMC gene) (Rubinstein et al., 1996) and found that they exhibited no significant changes in thermal or mechanical nociceptive thresholds with chronic UV exposure ( Figures 4A and 4B) . The b-endorphin null mice also failed to develop signs of opioid withdrawal ( Figure 4C ) and, when subjected to the conditionedplace aversion test, exhibited no measurable change in place preference ( Figure 4D ).
Keratinocyte Expression of p53 Is Required for Elevated b-Endorphin Levels and Pain Thresholds
The UV-induced cutaneous upregulation of POMC, the precursor to both a-MSH and b-endorphin, is mediated by the tumor suppressor p53, which directly activates POMC gene transcription in keratinocytes (Cui et al., 2007) . To test whether keratinocyte expression of p53 is required for UV-mediated increases in circulating b-endorphin, we crossed a mouse strain with a floxed allele of p53 with a strain containing cre under the control of the keratin 14 promoter, which is selective to keratinocytes. We subjected the p53fl/fl K14cre and control p53 +/+ K14cre mice to the UV-irradiation regimen and assayed plasma b-endorphin levels, mechanical nociception, and naloxone-induced conditioned place aversion. Consistent with the known role of p53 in the tanning response, there was an absence of any tanning on the ears of the p53fl/fl K14cre animals ( Figure 5A ). Further, we observed no increase in circulating b-endorphin ( Figure 5B ) or in mechanical nociception threshold ( Figure 5C ). Moreover, the K14cre control mice showed significant naloxone-conditioned place aversion compared to the p53fl/fl K14cre animals ( Figure 5D ). These data indicate that keratinocyte-derived b-endorphin is a key factor in mediating UV-induced addiction.
A B C D Figure 3. Chronically UV-Exposed Mice Show Symptoms of Opioid Dependence
(A) Signs of opioid withdrawal in mice under experimental conditions described in the figure: UV/saline (n = 9), mock/saline (n = 7), UV/naloxone (n = 15), and mock/naloxone (n = 7). Data are presented as the mean ± SEM; *p < 0.05 compared to UV/saline group by two-way ANOVA with Bonferroni multiple comparisons test. (B) Conditioned place aversion testing in UVtreated mice conditioned to the naloxone-paired box (black box) with an injection of naloxone or saline (white box) following 42 days of UV or mock treatment. Mice were permitted to freely move between naloxone-paired and saline-paired boxes prior to (pretest, n = 8) and after 4 days of conditioning (test), and place preferences were assessed as change in time spent in the naloxonepaired box (postconditioning À preconditioning). Data are presented as the mean ± SEM, and p values were generated by two-way ANOVA with Bonferroni multiple comparisons test.
(C) Morphine dose-response curves in mice following 42 days of UV irradiation (n = 31) or mock exposure (n = 29). Data are presented as the mean ± SEM; p < 0.0001 by two-way ANOVA.
(D) Conditioned place-preference testing in mice administered intravenous b-endorphin or saline through the tail vein. Mice were conditioned to b-endorphin (n = 6) or saline (n = 8) in the white box and saline in the black box. Place preferences were assessed as change in time spent in the white (b-endorphin)-paired box, postconditioning À preconditioning. Data are presented as the mean ± SEM; p = 0.0145 by Student's t test.
DISCUSSION
Our findings suggest that repeated UV exposure produces an opioid receptor-mediated addiction due to elevations in circulating b-endorphin, leading to increased nociceptive thresholds that are reversed by naloxone or ablated in b-endorphin null mice. Measurable withdrawal symptoms are elicited by naloxone, and proactive place-preference behaviors were strongly induced, based on prior conditioning between opioid receptor antagonism and cage color. Further, a skin-specific knockout of p53, a critical step in the UV-response pathway, prevented both the b-endorphin elevation and the behavioral responses. There remains a formal possibility that skin-specific p53 knockout could affect b-endorphin expression outside of the skin.
While these studies were performed in a nocturnal and furred animal model, significant evidence supports a strong relationship between UV exposure and addictive behaviors in humans (Feldman et al., 2004; Harrington et al., 2011; Kaur et al., 2005 Kaur et al., , 2006b Kourosh et al., 2010; Mosher and Danoff-Burg, 2010; Warthan et al., 2005; Zeller et al., 2006) . Several small studies have attempted to measure b-endorphin changes with UV exposure in humans (Gambichler et al., 2002; Kaur et al., 2006a; Levins et al., 1983; Wintzen et al., 2001) , with some showing UV-induced elevations and others not, although significant confounding variables complicate such measurements, such as diurnal variations in b-endorphin (McMurray et al., 1990) and stressors that also influence b-endorphin levels (Aravich et al., 1993; Gianoulakis et al., 1996; Petraglia et al., 1990; Welch et al., 1996) . While the effects of sunscreen have not been reported in this context, it does appear likely that sunscreen use would protect against UV-induced addictive behaviors.
Despite the carcinogenicity of UV and hence the serious maladaptive consequences of addiction to UV exposure, our results may also imply a potential evolutionary benefit of an endogenous mechanism that reinforces UV-seeking behavior, one that may operate by creating an opioid-mediated hedonic experience followed by dependence on the behavior to avoid the anhedonic consequences of withdrawal. Further studies may shed light on the site/sites of b-endorphin action within the brain and whether the brain regions and neuronal subpopulations involved in sun-seeking behavior are the same as those involved the analgesic response or in exogenous opioid addiction. A recent study has shown activation of known reward centers in the brains of volunteers during UV exposure (Harrington et al., 2012) .
The current studies suggest that UV exposure is biologically addictive but dangerous due to UV's mutagenic activities toward formation of all common forms of skin cancer. This calls into question the perceived safety of tanning beds and current benign views of indoor tanning, reflected in the United States' current Food and Drug Administration classification of UV-emitting devices as class I and therefore minimally regulated. It may be necessary, therefore, to more proactively protect individuals, including teens, from the risks of an avoidable, potentially lifethreatening exposure and to view recreational tanning and opioid drug abuse as engaging in the same biological pathway. /naloxone group by two-way ANOVA with Bonferroni multiple comparisons test; n > 7 for all groups. (D) Conditioned place aversion testing in UVtreated control and b-endorphin null mice conditioned to the naloxone-paired box (black box) with an injection of naloxone or saline. All mice were conditioned to saline in the white box; n > 10 for all groups. Mice were permitted to freely move between naloxone-paired and saline-paired boxes prior to and after 4 days of conditioning, and place preferences were assessed as change in time spent in the naloxone-paired box (postconditioning À preconditioning). Data are presented as the mean ± SEM; p values were generated by two-way ANOVA with Bonferroni multiple comparisons test. a floxed allele of p53 (Marino et al., 2000) and a keratin 14 promoter-driven Cre recombinase strain (Dassule et al., 2000) were used. All animal experiments were performed in accordance with institutional policies and Institutional Animal Care and Use Committee-approved protocols.
UV Irradiation and Blood Draws
Mice were dorsally shaved 2 days prior to the start of radiation exposure, then exposed to 50 mJ/cm 2 /day of UVB, an empirically determined suberythematic dose, 5 days per week (Monday-Friday) for 6 weeks. Mice were reshaved once every 2 weeks if there were patches of fur regrowth. For blood draws, mice were placed in a standard restrainer and tail vein blood was collected in EDTA microvette tubes containing 0.6 TIU aprotinin. Mice underwent blood draws prior to the stat of radiation exposure, once per week during the radiation exposure regimen, and once per week for 2 weeks following cessation of the UV regimen. Blood was drawn in the mornings prior to radiation exposure on Fridays.
Tubes of collected blood were maintained on ice until centrifugation at 3,500 rpm for 20 min at 4 C. Plasma was isolated, and samples were stored at À80 C until b-endorphin measurement. b-endorphin was quantified by radioimmunoassay (Phoenix Pharmaceuticals).
Straub Tail Measurement
Straub tail measurement was performed as described previously (Bilbey et al., 1960) . Scoring was on a scale of 0-2 according to the angle of elevation of the tail from the horizontal plane (0 = tail relaxed and no elevation; 1 = tail is rigid and elevated 1 -10 from horizontal; 1.5 = 11 -45 elevation and rigidity at the base of the tail; 2 = 46 -90 elevation with rigidity at the base of the tail).
For each time point, each mouse was scored every 10 s for 1 min, and the final score was the average of these six values. Mice undergoing the 6-week UV-exposure regimen or mock treatment were scored prior to the start of the regimen, once per week during the regimen, and once per week for 2 weeks following cessation of UV/mock treatment. On day 23 of the regimen after weekly Straub tail scoring, mice were injected intraperitoneally (i.p.) with either 10 mg/kg naloxone hydrochloride (Sigma) or saline. Mice underwent Straub tail scoring again 15 min following injection. 
Analgesic Threshold Testing
Mice underwent mechanical and thermal analgesic testing during UV/mock treatment regimens using the von Frey test (Kwan et al., 2006) and the hot-plate test, respectively (Mogil et al., 1999) . In the von Frey test, mice were placed in individual enclosures on an elevated wire mesh rack and the plantar surface of the left hind paw was serially poked with fibers of increasing tensile strength (ten times per fiber at a rate of 1/second) until a paw withdrawal response was elicited on two out of ten pokes. In the hot-plate test, mice were placed on a 52 C hot plate and time to response (paw flutter, paw licking, or jumping) was measured. Mice were habituated to the wire mesh rack for 30 min per day and to the hot plate at room temperature for 2 min per day for 3 days prior to measuring baseline nociceptive thresholds. Mice underwent nociceptive testing twice per week on nonconsecutive days during and for 2 weeks following cessation of UV/mock treatment. Mice received an intraperitoneal injection of 10 mg/kg naloxone or saline 15 min prior to nociceptive testing.
Somatic Symptoms of Opiate Withdrawal
Mice that had undergone 6 weeks of daily UV exposure or mock exposure were injected i.p. with either 2 mg/kg naloxone or saline, and signs of opioid withdrawal were tabulated as described elsewhere (Olson et al., 2006) . Mice were observed in an open-topped Plexiglas 30 cm 3 15 cm 3 15 cm rectangular container for 25 min each following injection, and signs of opioid withdrawal were tabulated. Wet dog shake, teeth chatter, and bouts of grooming were measured as occurrence in each 15 s interval. Individual rearing events were counted. Number of fecal pellets at the end of the 25 min interval was used to quantify diarrhea.
Conditioned Place Aversion Testing
The apparatus used consisted of a box with black interior and dim lighting and a box with white interior and bright lighting connected by a smaller gray ''neutral'' box, and procedures were followed as described previously (Skoubis et al., 2001; Weitemier and Murphy, 2009) . Mice that had undergone 6 weeks of daily UV exposure or mock exposure were tested for baseline place preferences prior to conditioning (10 min testing time per mouse). Over the following 4 days, conditioning took place in which mice were either conditioned with naloxone (10 mg/kg injection i.p.) or saline (injection i.p.) in the black box, and all animals were conditioned with saline (injection i.p.) in the white box. Conditioning time in each box was 30 min following injection. For each animal, there were 4 hr between conditioning in one box and condition in the other box each day. On the day following the final day of conditioning, place preferences were again tested (postconditioning, 10 min testing time per mouse).
Morphine Cross-Tolerance Testing Morphine dose-response curves in the hot-plate test were measured as described elsewhere (Mao et al., 2000) in mice that had undergone 6 weeks of UV exposure or mock treatment. Morphine was injected at a starting dose of 0.02 mg/kg i.p. and was increased logarithmically in cumulative dose increments of 0.3 log units. Thermal analgesic thresholds were tested 15 min after each morphine injection until there was failure to respond in the hot-plate test (cutoff time was 20 s) or until there was no change in response time from one dose to the next. There were 30 min between injections and 30 min between hot-plate testings for each mouse. Percent of maximal effect was calculated based on the equation: (test latency À baseline latency) / (maximal latency À baseline latency) 3 100% (Mao et al., 2000) .
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